In order to investigate the effect of HGCS on Hypercholesterolemia in rats diagnosed with hypertension, changes of related factors in blood and tissues of animal models were studied. The results are as following: At 250 ${mu}g/m{ell}$ or lower doses of HGCS, human fibroblast cells showed a survival rate of more than 90%. HGCS significantly reduced the total cholesterol and LDL cholesterol levels in blood observed in hypercholesterolemia rats. On the other hand, HGCS signicantly increased the blood HDL cholesterol level, compared to that of the control group. HGCS significantly reduced triglycerides caused by hypercholesterolemia. However, glucose level was decreased insignificantly. Significant decrease of hyperoxidative lipid level in tissues due to hypercholesterolemia was observed in HGCS treated group. Significant increase of SOD and catalase activities in tissues due to hypercholesterolemia were observed in HGCS treated group. From the results above, the anti-hypercholesterolemic effect of clinically used HGCS has been experimentally proved. More active prescription of HGCS to hypercholesterolemia and related patients should be available in the future.